Observation of therapeutic effect of escitalopram combined with lithium carbonate sustained-release tablets on patients with depression
苏国锋 1马晓燕 1周闯 2卜杨3
扫码查看
点击上方二维码区域，可以放大扫码查看
作者信息
1. 郑州市第九人民医院心理四病区，郑州 450053
2. 郑州市第九人民医院心理三病区，郑州 450053
3. 郑州市第九人民医院心理二病区，郑州 450053
折叠
摘要
目的 研究艾司西酞普兰联合碳酸锂缓释片治疗抑郁症的临床效果。 方法 队列研究。抽取2021年1月至2023年12月郑州市第九人民医院收治的抑郁症患者92例，采用随机数字表法分为单一用药组和联合用药组，每组46例。单一用药组采用艾司西酞普兰治疗，联合用药组采用艾司西酞普兰联合碳酸锂缓释片治疗。比较两组疗效、匹兹堡睡眠质量指数(PSQI)、汉密尔顿抑郁量表(HAMD)评分、蒙特利尔认知评估量表(MOCA)评分及不良反应。 结果 联合用药组总有效率(95.65%，44/46)高于单一用药组(80.43%，37/46)，P<0.05。治疗后，联合用药组PSQI低于单一用药组(P<0.05)；治疗后，联合用药组HAMD评分低于单一用药组，MOCA评分高于单一用药组(P<0.05)。联合用药组不良反应发生率(10.87%，5/46)与单一用药组(6.52%，3/46)比较，差异未见统计学意义(P>0.05)。 结论 艾司西酞普兰联合碳酸锂缓释片用于抑郁症中具有良好效果，能轻抑郁症状，提升其认知功能和睡眠质量，且联合用药安全性良好。 Objective To study the effect of escitalopram combined with lithium carbonate sustained-release tablets in the treatment of depression. Methods Ninety-two patients with depression admitted to the Ninth People’s Hospital of Zhengzhou from January 2021 to December 2023 were selected for the cohort study. The patients were divided into the single medication group and the combined medication group by random number table method, with 46 cases in each group. The single medication group was treated with escitalopram, and the combined medication group was treated with escitalopram combined with lithium carbonate sustained-release tablets. The treatment effects, Pittsburgh sleep quality index (PSQI), Hamilton depression scale (HAMD) score, Montreal cognitive assessment scale (MOCA) score and adverse reactions were compared between the two groups. Results The total effective rate of the combined medication group (95.65%, 44/46) was higher than that of the single medication group (80.43%, 37/46), P<0.05. After treatment, the PSQI of combined medication group was lower than that of single medication group (P<0.05). After treatment, the combined medication group had lower HAMD score and higher MOCA score than the single medication group (P<0.05). There was no significant difference in the incidence of adverse reactions between the combined medication group (10.87%, 5/46) and the single medication group (6.52%, 3/46),P>0.05. Conclusions Escitalopram combined with lithium carbonate sustained-release tablets has a good effect on depression it can alleviate depressive symptoms, improve cognitive function and sleep quality, with good drug safety.
Abstract
Objective To study the effect of escitalopram combined with lithium carbonate sustained-release tablets in the treatment of depression. Methods Ninety-two patients with depression admitted to the Ninth People’s Hospital of Zhengzhou from January 2021 to December 2023 were selected for the cohort study. The patients were divided into the single medication group and the combined medication group by random number table method, with 46 cases in each group. The single medication group was treated with escitalopram, and the combined medication group was treated with escitalopram combined with lithium carbonate sustained-release tablets. The treatment effects, Pittsburgh sleep quality index (PSQI), Hamilton depression scale (HAMD) score, Montreal cognitive assessment scale (MOCA) score and adverse reactions were compared between the two groups. Results The total effective rate of the combined medication group (95.65%, 44/46) was higher than that of the single medication group (80.43%, 37/46), P<0.05. After treatment, the PSQI of combined medication group was lower than that of single medication group (P<0.05). After treatment, the combined medication group had lower HAMD score and higher MOCA score than the single medication group (P<0.05). There was no significant difference in the incidence of adverse reactions between the combined medication group (10.87%, 5/46) and the single medication group (6.52%, 3/46),P>0.05. Conclusions Escitalopram combined with lithium carbonate sustained-release tablets has a good effect on depression it can alleviate depressive symptoms, improve cognitive function and sleep quality, with good drug safety.
万方数据